Opens in a new tab

Novo study finds semaglutide lowers BMI in children

Monday 16th November 2026 on 18:15 in Denmark

childhood obesity, Novo, semaglutide

A phase 3 study found that semaglutide significantly reduced body mass index among children aged 6 to 12 with severe obesity, DR reported, citing results released by Danish pharmaceutical company Novo.

After 68 weeks, average BMI had fallen by 17.4 per cent among children who received weekly semaglutide injections. In the placebo group, average BMI rose by 2.2 per cent.

The treatment was combined with a reduced-calorie diet and increased physical activity. The study, called STEP Young, included 167 children. It also found that 40.4 per cent of those given semaglutide were no longer classified as having severe obesity after treatment, compared with none in the placebo group.

Semaglutide is the active ingredient in the weight-loss medicine Wegovy. The study results have been published in the New England Journal of Medicine. Children aged 12 and older can currently be prescribed Wegovy in Denmark.

Novo research and development director Martin Holst Lange said obesity that begins in childhood can have lifelong consequences and that many children and young people still lack access to comprehensive treatment.

Source 
(via DR)